SCHEMBL31599425

SCHEMBL31599425

c1cnn(-c2ccc3c(c2)CCN3)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.45
DRD4 P21917 2/20 0.45
NOTUM Q6P988 1/20 0.45
TNIK Q9UKE5 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPK1 P28482 1/20 0.41
DRD3 P35462 1/20 0.39
KCNH2 Q12809 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AVPR2 P30518 1/20 0.37
PDK2 Q15119 1/20 0.37
ATM Q13315 1/20 0.37
CYP11B2 P19099 1/20 0.37
CHRNA7 P36544 1/20 0.37
CHRNA10 Q9GZZ6 1/20 0.37
CHRNA9 Q9UGM1 1/20 0.37
ERCC1 P07992 1/20 0.36
ERCC4 Q92889 1/20 0.36
CCNT1 O60563 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28324452 0.91 CYP11B2 (0.46) DRD2DRD4NOTUMTNIKALDH1A1
SCHEMBL24038599 0.79 PARP1 (0.47) DRD2NOTUMALDH1A1KDM4EMAPK1
SCHEMBL19260186 0.75 HDAC11 (0.43) DRD2DRD4NOTUMTNIKALDH1A1
SCHEMBL24038913 0.74 NOTUM (0.47) DRD2DRD4NOTUMALDH1A1KDM4E
SCHEMBL9088237 0.72 PDE3B (0.66) DRD2DRD4NOTUMCYP11B2TBXAS1
SCHEMBL1852193 0.72 ALDH1A1 (0.49) DRD2DRD4NOTUMTNIKALDH1A1
SCHEMBL4341894 0.71 NOTUM (0.78) DRD2DRD4NOTUMALDH1A1KDM4E
SCHEMBL3290710 0.71 CYP1A2 (0.44) NOTUMTNIKALDH1A1KDM4EMAPK1
SCHEMBL1997957 0.71 CYP11B2 (0.44) DRD2DRD4ALDH1A1KDM4ESMN1; SMN2
SCHEMBL27742475 0.70 DRD2 (0.50) DRD2DRD4ALDH1A1KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 DRD2 4529/4885DRD4 4727/4885NOTUM 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.